Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction

The fibrosis biomarker galectin-3, but not sST2, taken immediately after MI, predicts LVEF and infarct size after 4 months. We hypothesize that galectin-3 may play a role in the pathophysiology of cardiac remodeling after acute MI.